The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pliant Therapeutics (PLRX – Research Report) and Capricor ...

NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The clinical-stage ...

The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...

Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial's independent ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...